<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Lobaccaro, J.M.</title>
    <link>http://repub.eur.nl/res/aut/9310/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Substitution of Ala564 in the first zinc cluster of the deoxyribonucleic acid (DNA)-binding domain of the androgen receptor by Asp, Asn, or Leu exerts differential effects on DNA binding (Article)</title>
      <link>http://repub.eur.nl/res/pub/8755/</link>
      <pubDate>1998-01-01T00:00:00Z</pubDate>
      <description>In the androgen receptor of a patient with androgen insensitivity, the
          alanine residue at position 564 in the first zinc cluster of the
          DNA-binding domain was substituted by aspartic acid. In other members of
          the steroid receptor family, either valine or alanine is present at the
          corresponding position, suggesting the importance of a neutral amino acid
          residue at this site. The mutant receptor was transcriptionally inactive,
          which corresponded to the absence of specific DNA binding in gel
          retardation assays, and its inactivity in a promoter interference assay.
          Two other receptor mutants with a mutation at this same position were
          created to study the role of position 564 in the human androgen receptor
          on DNA binding in more detail. Introduction of asparagine at position 564
          resulted in transcription activation of a mouse mammary tumor virus
          promoter, although at a lower level compared with the wild-type receptor.
          Transcription activation of an (ARE)2-TATA promoter was low, and binding
          to different hormone response elements could not be visualized. The
          receptor with a leucine residue at position 564 was as active as the
          wild-type receptor on a mouse mammary tumor virus promoter and an
          (ARE)2-TATA promoter, but interacted differentially with several hormone
          response elements in a gel retardation assay. The results of the
          transcription activation and DNA binding studies could partially be
          predicted from three-dimensional modeling data. The phenotype of the
          patient was explained by the negative charge, introduced at position 564.</description>
    </item>
  </channel>
</rss>